Gender difference in response to COVID vaccination; a letter to the editor on current findings

Leila Alem1, Hamid Nasri1, Zahra Mojtahedi2*

1Nickan Research Institute, Isfahan, Iran
2School of Public Health, University of Nevada, Las Vegas, USA

Correspondence to:
Zahra Mojtahedi, Email: mojtahedi@unlv.nevada.edu

Received: 7 May 2023
Accepted: 10 July 2023
ePublished: 31 July 2023

Abstract

Implication for health policy/practice/research/medical education:
This study found a difference in the immune response to the COVID vaccine between men and women. Women will have a more robust immune response and show more complications.

Keywords: COVID-19, Vaccines, Gender differences, Pandemic, SARS-CoV-2

To Editor,
SARS-CoV-2 is a highly infectious and contagious coronavirus that appeared at the end of 2019 and has triggered a respirational disorder called COVID-19 that affects public health (1). SARS-CoV-2, which was discovered in Wuhan, China, is a contagious virus that spreads swiftly by respiratory secretions (sneeze, cough) or close individual contacts with an infected individual (2). Coronavirus is a warning for global hygiene, affecting people in many nations (3), with over six million deaths recorded worldwide (4). While the majority of patients have mild to severe symptoms such as cough, fever, dyspnea, or loss of taste and smell, around 15% of patients develop pneumonia that requires supplemental oxygen and 5% develop respiratory failure and acute respiratory distress syndrome (ARDS) (5,6). Studies show that men are less likely than women to make an effort to reduce the transmission of viruses. Different gender theories, beliefs, and practices influenced the initial phases of COVID-19 (7). The spread of the disease has caused the rapid manufacturing and growth of COVID-19 vaccines; terminating the contagion is done by vaccines (4).

Vaccination is the most effective method of preventing the spread of infection (8). The COVID-19 vaccination was the most successful vaccination platform in the National Health Service's history (9). The general acceptance of COVID-19 vaccination in Geneva was 71.8%, with males being more accepting than females, older people being more accepting than younger people and urban regions being more accepting than rural ones (10). The COVID-19 vaccination has resulted in numerous adverse effects. Myalgia, arthralgia, fever, weakness, headache, and discomfort or inflammation at the injection site are common complications after vaccination. In rare cases, it has been linked to neurological adverse effects such as cerebral venous sinus thrombosis, Bell's palsy, acute transverse myelitis, acute disseminated encephalomyelitis, and polyneuropathy (11). The outcome of different respiratory viral infections is influenced by gender. Respiratory viral diseases such as influenza, syncytial virus, and coronavirus differ between genders throughout life. Both genders are equally susceptible to infection; however, males are more vulnerable to mortality and morbidity. Investigations have revealed various responses to viral infections such as COVID-19. Women are more prone than men to have severe outcomes during reproductive times. Gender and pregnancy have an impact on disease processes.

Furthermore, to investigate gender variations in infection pathogenesis, men and women respond differently to treatment. Variations in chromosomal content, hormone profile, and sexual performance have all been proposed as important factors. Women's immunological responses are often more significant and appear to produce more antibodies; however, they suffer more severe outcomes than men (12,13).
The X chromosome is implicated in immune function regulation (14). Jensen et al. demonstrated that men and women responded differently to numerous vaccines introduced since the discovery of COVID-19 vaccines in 2020 (15). Furthermore, Fischinger et al. discovered that females have higher antibody responses and experience more adverse effects than males (16). As a result, men and women have different immunological reactions to the COVID vaccine. Women will have a more robust immune response and show more complications.

Authors’ contribution

Conceptualization: Hamid Nasri.
Data curation: Hamid Nasri and Leila Alem.
Funding acquisition: Hamid Nasri.
Investigation: Leila Alem.
Resources: Hamid Nasri.
Validation: Hamid Nasri and Leila Alem.
Supervision: Hamid Nasri.
Writing—original draft: Leila Alem.
Writing—review and editing: Leila Alem, Zahra Mojtahedi.

Conflicts of interest

The authors declare that they have no competing interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support

None.

References